NCT02610140 2020-11-04Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)BayerPhase 2 Completed248 enrolled 23 charts
NCT00597116 2016-10-10An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant MesotheliomaSanofiPhase 2 Terminated25 enrolled 8 charts